Pembrolizumab Dosing Schedules
Pembrolizumab, marketed as Keytruda, is administered intravenously, and its dosing frequency depends on the specific cancer being treated and the dosage strength.
How Often is Pembrolizumab Given?
For most indications, pembrolizumab is administered every three weeks [1][2]. In some cases, a less frequent schedule of every six weeks is also an option [1][2]. The specific regimen is determined by the treating physician based on established treatment guidelines for the patient's condition.
What is the Standard Dosage of Pembrolizumab?
The standard dosage of pembrolizumab is typically 200 mg administered over 30 minutes [1][2]. For some specific cancer types, such as melanoma or certain types of lung cancer, higher doses like 400 mg administered every six weeks are also used [1][2].
When Does Pembrolizumab Treatment End?
The duration of pembrolizumab treatment varies. For some cancers, like unresectable or metastatic melanoma, treatment continues until disease progression, unacceptable toxicity, or for a maximum of 24 months in the adjuvant setting [1][2]. For other indications, such as certain types of metastatic non-small cell lung cancer, treatment continues until disease progression, unacceptable toxicity, or for up to two years in the curative-intent setting [1][2].
What Factors Influence Pembrolizumab Dosing?
Several factors influence the dosing of pembrolizumab, including the type and stage of cancer, the patient's overall health, and whether the drug is being used alone or in combination with other therapies [1][2]. The treating oncologist will consider these factors to establish the most appropriate and effective treatment plan.
Are There Different Dosing Schedules for Pembrolizumab?
Yes, there are different dosing schedules for pembrolizumab. The most common schedules are every three weeks and every six weeks [1][2]. The choice between these schedules is guided by the specific cancer indication and physician preference.
Sources:
[1] https://www.drugpatentwatch.com/drugs/pembrolizumab
[2] https://www.keytruda.com/how-it-works/dosing-and-administration/